Ernst & Young Reports Accelerated Pharmaceutical Expansion In China
This article was originally published in PharmAsia News
Ernst & Young recently conducted a survey on 40 high-level executives in 15 leading pharmaceutical companies operating in China. According to the findings, China will be one of the most important growing markets in the next several years thanks to healthcare plan extension and rising wealth, which will increase demand for drugs. Ernst & Young notes that global pharmaceutical firms' expansion of their China businesses reflects the huge development opportunities arising from the local population's growing purchasing power and greater coverage of health insurance, led by a burgeoning middle class. However, the country's commercial complexities will force enterprises to seek more flexible and innovative business models. The report surmises that strength in execution will be especially critical. (Click here for more - Chinese Language)
You may also be interested in...
Mooted some time ago, the Medicare Part D Drug Rebate Rule and the Medicare Part B Most-Favored-Nation Model have now been finalized by US President Donald Trump. But US off-patent body the Association for Accessible Medicines feels “further action is necessary.”
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.